Clinical trials: Metastatic Digestive System Carcinoma
CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
To explore the possibility to overcome CYP3A-mediated resistance to anticancer drugs in pancreatic cancer, we will investigate the pharmacokinetics, safety, tolerability, and efficacy of nanoparticle albumin-bound paclitaxel…
- Conditions
- CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- IntenSify (NCT05494866)
- Testing
- Cobicistat Oral Tablet, Gemcitabin, Nab paclitaxel
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- German Cancer Research Center
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Gastric Cancer
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
This study will be conducted to understand real-world treatment patterns, participant characteristics (demographic and clinico-pathological characteristics), clinical outcomes and safety of different treatment regimens, and…
- Trial name
- NCT05606094
- Where
- 31 sites in China, Hong Kong and 2 more
- Volunteers
- 450 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Liver Tumours, Liver Cancer (Primary and Metastatic)
Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy
The goal of this national mutlticenter observational study is to learn and describe trends over time in the use of techniques for inducing hepatic hypertrophy in Italy.
- Conditions
- Liver Tumours, Liver Cancer (Primary and Metastatic), Liver Resection, Liver Hypertrophy
- Trial name
- I-GROWtoh (NCT07445412)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Colorectal Cancer, Liver Metastases
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective.
- Conditions
- Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases
- Trial name
- NCT03366155
- Testing
- Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).
The PULSAR trial is an international, investigator-initiated, single arm open-label phase II study. The aim of this study is to measure the clinical activity of the combination FOLFIRI-aflibercept in an homogeneous group of…
- Trial name
- PULSAR (NCT02173990)
- Testing
- Aflibercept-FOLFIRI
- Where
- 8 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Oscar Lambret
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Advanced Solid Tumor, Ovarian Cancer
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary
- Trial name
- NCT05252390
- Testing
- NUV-868, Olaparib, Enzalutamide
- Where
- 22 sites in United States, Australia
- Volunteers
- 82 people
- Sponsor
- Nuvation Bio Inc.
Esophageal Squamous Carcinoma Cell
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
Effective later-line treatment options remain an unmet medical need for patients with advanced esophageal squamous cell carcinoma (ESCC) whose disease has progressed after prior immunotherapy, particularly given the widespread…
- Trial name
- NCT07688291
- Testing
- PD-1/IL-2α-bias bispecific antibody fusion protein
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing GoBroad Hospital
Peritoneal Diseases
ERAS® Guidelines Validation of CRS With or Without HIPEC
Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative…
- Trial name
- NCT05185791
- Testing
- Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 288 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Carcinoma
Axitinib as Maintenance Treatment in Patients With Metastatic CRC
The purpose of this study is to evaluate the maintenance therapy with axitinib in patients with metastatic colorectal carcinoma
- Trial name
- TTD-11-01 (NCT01483638)
- Testing
- axitinib
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Carcinoma in the Liver, MLH1 Gene Mutation
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab work in treating patients with microsatellite stable colorectal cancer that has spread to the liver.
- Conditions
- Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation
- Trial name
- NCT03005002
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Liver Cancer
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
RATIONALE: Panobinostat and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of liver cancer by blocking blood flow to the tumor.
- Trial name
- NCT00873002
- Testing
- panobinostat, sorafenib tosylate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has…
- Trial name
- NCT06339619
- Testing
- Adebrelimab, Apatinib, Tegafur
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pancreatic Tumor, Periampullary Carcinoma Resectable
Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors
This multicentre, prospective and randomized study aims(1:1) to compare the rate of recurrence, metastasis and survival according to the levels of intraoperative circulating tumor cells (CTCs) during cephalic…
- Conditions
- Pancreatic Tumor, Periampullary Carcinoma Resectable, Circulating Tumor Cells, Metastasis
- Trial name
- CETUPANC (NCT03340844)
- Testing
- No Touch (NT), Superior Mesenteric Artery First (SMA)
- Where
- Spain
- Volunteers
- 86 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Colorectal Cancer
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.
- Trial name
- CC6 (NCT02118064)
- Testing
- G17DT-Irinotecan
- Volunteers
- 161 people
- Sponsor
- Cancer Advances Inc.
Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
This phase II trial studies the side effects of epacadostat and pembrolizumab and to see how well they work before surgery in treating participants with stage II-III esophageal or gastroesophageal cancer.
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03592407
- Testing
- Epacadostat, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Colorectal Cancer, Colorectal Carcinoma
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- NCT00478634
- Testing
- RAD001, Cetuximab, Irinotecan
- Where
- 16 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.